A molecular switch in breast cancer cells reprograms the genetic production line towards tumor growth and stress resistance.

Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

The Fugaku supercomputer builds a highly detailed virtual mouse cortex with millions of neurons enabling unprecedented ...

Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.

DeepTarget is a computational tool that integrates large-scale drug screens with omics data to predict mechanisms of cancer cell killing.

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

Prophylactic HPV vaccines prevent infection but not existing disease. A nasal nanogel vaccine shows preclinical promise for ...

Microrobots could be precisely directed, under clinical conditions, by integrating systems for navigation, therapeutic ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

The data, which is being presented at this year's AMP meeting, offers some insights into the often hidden causes of recurrent pregnancy loss.

Animal testing is costly, slow, and poorly predictive. ORIVA offers a human-relevant alternative with the potential to change that.